Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Collaborator: Genentech, Inc.
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• provide written informed consent

• 21 years of age or older

• new onset, within 14 days, of ischemia and vision loss

• Best Corrected Visual Acuity (BCVA) 20/40 or worse

Exclusion Criteria:

• pregnancy or lactation

• proliferative diabetic retinopathy,

• diabetic macular edema,

• uveitis,

• history of ocular trauma,

• severe glaucoma,

• age-related macular degeneration.

• prior or concomitant treatment of oral steroids within 30 days,

• participation in any studies of investigational drugs within 30 days,

• participation in a ranibizumab clinical trial or,

• prior treatment intravitreally or intravenously of Avastin or steroids.